Comparing the efficiency of Fib‐4, Egy‐score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C

Assessment of hepatic fibrosis in chronic hepatitis C virus patients by liver biopsy is not widely accepted despite its accuracy, being invasive, carrying complications, and adding cost. This paved the way to development and use of non‐invasive markers of fibrosis in diagnosis of hepatic fibrosis. We aimed at evaluating the efficiency of Fib‐4, Egy‐score, Aspartate‐to‐platelet ratio index (APRI), and Göteborg University Cirrhosis Index (GUCI) in comparison to liver biopsy, in the assessment of hepatic fibrosis in chronic hepatitis C patients. This was a cross sectional study including 200 chronic HCV patients were divided into two groups according to stage of fibrosis (Metavir score) into non‐significant fibrosis (0.48, Egy‐score >0.73, and GUCI >0.57 significantly predict significant fibrosis (P 1.27) is the best method of prediction of significant fibrosis compared to Egy‐score, APRI, and GUCI. Addition of BMI to Fib‐4 did not improve diagnostic value of Fib‐4.